Literature DB >> 10943865

Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms.

D L Mattey1, A H Hajeer, A Dababneh, W Thomson, M A González-Gay, C García-Porrúa, W E Ollier.   

Abstract

OBJECTIVE: To determine whether giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are associated with different tumor necrosis factor (TNF) microsatellite polymorphisms.
METHODS: Typing of TNF microsatellite polymorphisms was carried out by molecular-based techniques on DNA obtained from a population sample of residents from Lugo, northwestern Spain. A case-control approach was used to compare 136 patients with GCA and/or PMR with 147 ethnically matched controls. The association of disease with TNF microsatellite polymorphisms was investigated using chi-square tests and multivariate logistic regression analyses.
RESULTS: Different TNF microsatellite associations were found with GCA and PMR. In patients with isolated GCA, the primary association was with TNFa2, which was independent of the GCA associations with HLA-DRB1*0401 and *0101. A negative association was found with TNFa10. In patients with isolated PMR, there was a positive association with TNFb3. This was found to be independent of the HLA-DRB1*13/*14 association in isolated PMR. TNFd4 was negatively associated with isolated PMR. Forward stepwise logistic regression analyses indicated that the strongest association with GCA was provided by the TNFa2 allele, although DRB1*0401 and *0101 were still associated. PMR was primarily associated with TNFb3. A direct comparison of TNF allele frequencies between isolated GCA and isolated PMR indicated that the main difference between these conditions occurred in the frequency of TNFa10.
CONCLUSION: GCA and PMR in individuals from northwestern Spain are associated with different TNF microsatellite polymorphisms. The primary TNF associations (TNFa2 and TNFb3) appear to influence susceptibility to these conditions independent of any HLA-DRB1 association.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10943865     DOI: 10.1002/1529-0131(200008)43:8<1749::AID-ANR11>3.0.CO;2-K

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

1.  Treatment of refractory temporal arteritis with adalimumab.

Authors:  M Mubashir Ahmed; Eisha Mubashir; Samina Hayat; Marjorie Fowler; Seth Mark Berney
Journal:  Clin Rheumatol       Date:  2006-08-30       Impact factor: 2.980

Review 2.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  Cytokine gene considerations in giant cell arteritis: IL10 promoter polymorphisms and a review of the literature.

Authors:  Lorena Alvarez-Rodriguez; Marcos Lopez-Hoyos; Eugenio Carrasco-Marín; Gaurav Tripathi; Pedro Muñoz Cacho; Cristina Mata; Jaime Calvo-Alen; Maite Garcia-Unzueta; Elena Aurrecoechea; Victor Manuel Martinez-Taboada
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

4.  Utility of temporal artery biopsy samples for genome-wide analysis of giant cell arteritis.

Authors:  K Cremin; P Leo; J E Harris; E De Smit; L Bradbury; P McKelvie; C L Hill; M A Brown; A W Hewitt
Journal:  Genes Immun       Date:  2014-05-15       Impact factor: 2.676

5.  Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis.

Authors:  M Cutolo; C M Montecucco; L Cavagna; R Caporali; S Capellino; P Montagna; L Fazzuoli; B Villaggio; B Seriolo; A Sulli
Journal:  Ann Rheum Dis       Date:  2006-04-27       Impact factor: 19.103

Review 6.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

Review 7.  Large-vessel vasculitis.

Authors:  Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun
Journal:  Nat Rev Dis Primers       Date:  2022-01-06       Impact factor: 65.038

8.  Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis.

Authors:  Rogelio J Palomino-Morales; Tomas R Vazquez-Rodriguez; Orlando Torres; Inmaculada C Morado; Santos Castañeda; Jose A Miranda-Filloy; Jose L Callejas-Rubio; Benjamin Fernandez-Gutierrez; Miguel A Gonzalez-Gay; Javier Martin
Journal:  Arthritis Res Ther       Date:  2010-03-23       Impact factor: 5.156

9.  Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis.

Authors:  Ann W Morgan; Jim I Robinson; Jennifer H Barrett; Javier Martin; Amy Walker; Sarah J Babbage; William E R Ollier; Miguel A Gonzalez-Gay; John D Isaacs
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 10.  Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica.

Authors:  M A Gonzalez-Gay
Journal:  Arthritis Res       Date:  2001-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.